Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma

被引:13
|
作者
De Rosa, Anna [1 ]
Fornili, Marco [2 ]
Maestri Tassoni, Michelangelo [1 ]
Guida, Melania [1 ]
Baglietto, Laura [2 ]
Petrucci, Loredana [1 ]
Chella, Antonio [3 ]
Melfi, Franca [4 ]
Lucchi, Marco [5 ]
Ricciardi, Roberta [1 ,5 ]
机构
[1] Univ Pisa, Neurol Unit, Dept Clin & Expt Med, Via Paradisa 2, I-56124 Pisa, Italy
[2] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
[3] Univ Hosp Pisa, Unit Pneumol, Dept Cardiol Thorac & Vasc Med, Pisa, Italy
[4] Univ Pisa, Robot Multispecialty Ctr Surg, Minimally Invas & Robot Thorac Surg, Dept Cardiol Thorac & Vasc Med, Pisa, Italy
[5] Univ Hosp Pisa, Dept Cardiol Thorac & Vasc Med, Pisa, Italy
关键词
Antiacetylcholine receptor antibody; myasthenia gravis; thymoma; thymoma recurrence; THYMECTOMY; THERAPY;
D O I
10.1111/1759-7714.13724
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Thymoma-associated myasthenia gravis (TAMG) is one of the subtypes of myasthenia gravis with autoantibodies against the acetylcholine receptor (AChR-Ab). We analyzed the clinical features of our cohort of TAMG patients and the changes in AChR-Ab titer before and after thymectomy in order to identify factors predicting thymoma relapses. Methods We retrospectively assessed: age of MG onset, MG clinical status according to MGFA (Myasthenia Gravis Foundation of America), epoch of thymectomy, post-thymectomy status, oncological features and surgical approach. AChR-Ab dosages were measured both before and after thymectomy. Linear regression models were applied to identify clinical determinants of AChR-Ab titers and the Cox regression model was fitted to estimate the factors associated with the risk of thymoma recurrence. Results The study sample included 239 MG patients, 27 of whom experienced one or more recurrences (median follow-up time: 4.8 years). The AChR-Ab titers decreased after first thymectomy (P < 0.001); the decrease was more pronounced in female patients (P = 0.05), in patients diagnosed with MG at an older age (P = 0.003), and in those who had lower MG stage before surgery (P = 0.02) or higher Masaoka-Koga stage (P = 0.005). The risk of relapse was closely linked with the age of the patient, the Masaoka-Koga stage and the surgical approach. Conclusions Presurgery levels of AChR-Ab or their change after surgery were not associated with thymoma recurrence. The reduction of AChR-Ab titers after thymectomy confirms an immunological role of thymoma in the pathogenesis of MG. Key points Significant findings of the study: Young MG patients with an advanced Masaoka staging score of the primary tumor who underwent thymectomy with approaches different from sternotomy and VATS should be monitored for high risk of recurrence. What this study adds: No other study has ever investigated the changes in AChR-Ab titers before and after thymectomy in a large cohort of TAMG patients. The reduction of AChR-Ab titers after thymectomy suggests an immunological role of thymoma in the pathogenesis of MG.
引用
收藏
页码:106 / 113
页数:8
相关论文
共 50 条
  • [1] Thymoma-associated myasthenia gravis without acetylcholine receptor antibodies
    Rigamonti, Andrea
    Lauria, Giuseppe
    Piamarta, Francesca
    Fiumani, Anna
    Agostoni, Elio
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 302 (1-2) : 112 - 113
  • [2] Thymoma-associated myasthenia gravis: clinical features and surgical results
    Yuceyar, A. N.
    Uluakay, A.
    Uncu, G.
    Ekmekci, O.
    Karasoy, H.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 721 - 721
  • [3] Thymoma-associated myasthenia gravis: Clinical features and surgical results
    Bouchikh, M.
    El Malki, H. O.
    Ouchen, F.
    Achir, A.
    Benosman, A.
    [J]. REVUE NEUROLOGIQUE, 2013, 169 (11) : 879 - 883
  • [4] Evolution of thymoma-associated Myasthenia gravis
    Nacu, A.
    Lisnic, V.
    Munteanu, L.
    Grosu, C.
    [J]. JOURNAL OF NEUROLOGY, 2012, 259 : S208 - S208
  • [5] Clinical characteristics and outcomes of thymoma-associated myasthenia gravis
    Alvarez-Velasco, Rodrigo
    Gutierrez-Gutierrez, Gerardo
    Carlos Trujillo, Juan
    Martinez, Elisabeth
    Segovia, Sonia
    Arribas-Velasco, Marina
    Fernandez, Guillermo
    Paradas, Carmen
    Velez-Gomez, Beatriz
    Casasnovas, Carlos
    Nedkova, Velina
    Guerrero-Sola, Antonio
    Ramos-Fransi, Alba
    Martinez-Pineiro, Alicia
    Pardo, Julio
    Sevilla, Teresa
    Gomez-Caravaca, Maria Teresa
    Lopez de Munain, Adolfo
    Jerico, Ivonne
    Pelayo-Negro, Ana L.
    Asuncion Martin, Maria
    Morgado, Yolanda
    Dolores Mendoza, Maria
    Perez-Perez, Helena
    Rojas-Garcia, Ricard
    Turon-Sans, Janina
    Querol, Luis
    Gallardo, Eduard
    Illa, Isabel
    Cortes-Vicente, Elena
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (06) : 2083 - 2091
  • [6] Thymoma-Associated Myasthenia Gravis With Myocarditis
    Sarwar, Shihab
    Oyewunmi, Oyebimbola
    Bhola, Karundat
    Heydari, Bobak
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
  • [7] Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis
    Torres-Vega, Estefania
    Mancheno, Nuria
    Cebrian-Silla, Arantxa
    Herranz-Perez, Vicente
    Chumillas, Maria J.
    Moris, German
    Joubert, Bastien
    Honnorat, Jerome
    Sevilla, Teresa
    Vilchez, Juan J.
    Dalmau, Josep
    Graus, Francesc
    Manuel Garcia-Verdugo, Jose
    Bataller, Luis
    [J]. NEUROLOGY, 2017, 88 (13) : 1235 - 1242
  • [8] Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor
    Maggi, Lorenzo
    Andreetta, Francesca
    Antozzi, Carlo
    Confalonieri, Paolo
    Cornelio, Ferdinando
    Scaioli, Vidmer
    Mantegazza, Renato
    [J]. NEUROMUSCULAR DISORDERS, 2008, 18 (08) : 678 - 680
  • [9] Immunodeficiency in patients with thymoma-associated myasthenia gravis
    Ishizuchi, Kei
    Takizawa, Tsubasa
    Ohnuki, Yuko
    Sekiguchi, Koji
    Motegi, Haruhiko
    Oyama, Munenori
    Nakahara, Jin
    Shiina, Takashi
    Suzuki, Shigeaki
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2022, 371
  • [10] Clinical and pathologic predictors of outcome in thymoma-associated Myasthenia gravis
    López-Cano, M
    Ponseti-Bosch, JM
    Espin-Basany, E
    Sánchez-García, JL
    Armengol-Carrasco, M
    [J]. ANNALS OF THORACIC SURGERY, 2003, 76 (05): : 1643 - 1649